|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS12330 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-SPP/Signal Peptide Peptidase |
| 克隆性 | 是 |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human Signal Peptide Peptidase |
產(chǎn)品訂購信息：
英文名稱 Anti-SPP/Signal Peptide Peptidase
中文名稱 信號(hào)肽肽酶SPP抗體規(guī)格
別 名 Histocompatibility (minor) 13; HM 13; HM13; HM13_HUMAN; IMP 1; IMP-1; IMP1; IMPAS; IMPAS-1; Intramembrane Protease 1; Intramembrane protease; Minor Histocompatibility 13; Minor histocompatibility antigen 13; Minor histocompatibility antigen H13; MSTP086; Presenilin like protein 3; Presenilin-like protein 3; PSENL 3; PSENL3; PSL 3; PSL3; Signal peptide peptidase; Signal peptide peptidase beta; SPP; dJ324O17.1; H13; hIMP1; hIMP1 protein.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit
產(chǎn)品類型 一抗
研究領(lǐng)域 免疫學(xué) 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo)
蛋白分子量 predicted molecular weight: 42kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human Signal Peptide Peptidase
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
信號(hào)肽肽酶SPP抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 The endoplasmic reticulum exerts a quality control over newly synthesized proteins and a variety of components have been implicated in the specific recognition of aberrant or misfolded polypeptides. Signal peptide peptidase (SPP) catalyzes intramembrane proteolysis of some signal peptides after they have been cleaved from a preprotein, resulting in the release of the fragment from the ER membrane into the cytoplasm. SPP is required to generate lymphocyte cell surface (HLA-E) epitopes derived from MHC class I signal peptides, and may play a role in graft rejection. It also may be necessary for the removal of the signal peptide that remains attached to the hepatitis C virus core protein after the initial proteolytic processing of the polyprotein.
Function : Catalyzes intramembrane proteolysis of some signal peptides after they have been cleaved from a preprotein, resulting in the release of the fragment from the ER membrane into the cytoplasm. Required to generate lymphocyte cell surface (HLA-E) epitopes derived from MHC class I signal peptides. May play a role in graft rejection. May be necessary for the removal of the signal peptide that remains attached to the hepatitis C virus core protein after the initial proteolytic processing of the polyprotein. Involved in the intramembrane cleavage of the integral membrane protein PSEN1.
Subcellular Location : Endoplasmic reticulum membrane; Multi-pass membrane protein. Isoform 4: Cell membrane; Multi-pass membrane protein.
Tissue Specificity : Widely expressed with highest levels in kidney, liver, placenta, lung, leukocytes and small intestine and reduced expression in heart and skeletal muscle. Expressed abundantly in the CNS with highest levels in thalamus and medulla.
Post-translational modifications : N-glycosylated.
Similarity : Belongs to the peptidase A22B family.
哥倫比亞瓊脂培養(yǎng)基250g用于梭菌分離培養(yǎng)
麥芽浸膏湯 200(g) incubation media 麥芽浸膏湯 200(g)
念珠菌顯色培養(yǎng)基 1000ml/瓶 用于念珠菌特別是白色念珠菌的選擇性分離和初步鑒別
泛酸測定培養(yǎng)基250用于*食品和乳粉中泛酸測定incubationmedia泛酸測定培養(yǎng)基250用于*食品和乳粉中泛酸測定
PolyPeptoneYeastExtractMedium
哥倫比亞血瓊脂基礎(chǔ)250g營養(yǎng)非常豐富，用于各種細(xì)菌的基礎(chǔ)培養(yǎng)基
CZAPEK-DOX agar 查貝克-多克斯瓊脂 1.05460.0500 MERCK默克 incubation media CZAPEK-DOX agar 查貝克-多克斯瓊脂 1.05460.0500 MERCK默克
萬古霉素(改良月桂基鹽胰蛋白胨肉湯凍干配套試劑) 10支/盒 每支添加于100ml(022212)中配成MLST
胎兒骨髓間質(zhì)干細(xì)胞成脂誘導(dǎo)分化培養(yǎng)基Fetalbonemarrowmesenchymalstemcellsintotheculturemediuminduceddifferentiationoffat
FraserSupplement
尿素酶瓊脂基礎(chǔ)250g生化培養(yǎng)基，用于細(xì)菌脲酶檢測(GB、SN標(biāo)準(zhǔn))
Mediaforisolationofmagnetotacticbacteria
乳糖蛋白胨培養(yǎng)液 Lactose Peptone Broth 250 用于飲用水，水源水中總大腸菌群的測定(GB標(biāo)準(zhǔn))
HB培養(yǎng)基250g/瓶用于植物組織培養(yǎng)incubationmediaHB培養(yǎng)基250g/瓶用于植物組織培養(yǎng)
FB1(Half-Fraser)添加劑(A、B) 2ml/支*40 每支添加到225ml HBJ006中
CL-0247ZR-75-1(人癌細(xì)胞)5×106cells/瓶×2
NRG1 Others Human 人 NRG1-alpha (ECD) 人細(xì)胞裂解液 (陽性對(duì)照)
小鼠甲狀腺上皮細(xì)胞完全培養(yǎng)基 100mL
Sf9昆蟲卵巢細(xì)胞 Sf9 insect ovarian cells GPM-115無血清無蛋白昆蟲細(xì)胞懸浮培養(yǎng)基(金普諾安 Cat#GPM001L01)
IL1A Protein Human 重組人 IL-1 alpha / IL1A / IL1F1 蛋白
PC-3M-IE8(人高轉(zhuǎn)移細(xì)胞株) 5×106cells/瓶×2 Lec1(卵巢細(xì)胞)
信號(hào)肽肽酶SPP抗體規(guī)格CL-0244WISH(人羊膜細(xì)胞)5×106cells/瓶×2
SRGN Others Human 人 Serglycin / SRGN 人細(xì)胞裂解液 (陽性對(duì)照)
人骨骼肌細(xì)胞cDNAHSkMC cDNA
4T1細(xì)胞，人癌細(xì)胞 昆蟲細(xì)胞系,Sf-21細(xì)胞 肺微內(nèi)皮細(xì)胞Many types of cells包裝：5 × 105次方(1ml)
Y3-Ag 1.2.3(大鼠細(xì)胞) 5×106cells/瓶×2
NHDF adult Pellet 正常人皮膚成纖維細(xì)胞團(tuán)塊(捐獻(xiàn)者) > 1 mio.cells CCCSCK
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 信號(hào)肽肽酶SPP抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）信號(hào)肽肽酶SPP抗體規(guī)格 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
